Plains GP Holdings, L.P. PAGP ← Back to all reports

Plains GP Holdings, L.P.

PAGP · Energy
A ★★★★ Buy
Aug 17, 2026 · Score 90 · Type A — Value-style analysis Used for established, cash-generative companies — weighs earnings power, valuation against the company's own history and peers, and margin of safety. Full methodology →
Current PriceThe market price around the time this report was written — not a live quote. The market has moved since; check a current price before acting.Methodology → $25.84
Buy ZoneThe large figure is the midpoint of the suggested buy range shown in parentheses. $24.00 ($23.00–$25.00)
Price TargetOur estimated fair value. For richly valued stocks it can sit below the current price — see Methodology.Methodology → $30.51
Expected Return
  • Target relative to the Current Price ((Target − Current) ÷ Current). Since that price is from the report date, your actual return will differ.
  • A negative figure isn't an error. For richly valued stocks, the fair-value target can sit below the current price, so the return reads negative. The grade reflects company quality; this figure reflects today's entry valuation.
Methodology →
+18.1%

Type A - Plains GP Holdings, L.P. (PAGP) 20260817 Stock Analysis

📅 Plains GP Key Upcoming Events

🏢 Step 1: Plains GP Company Overview & Business Model

Q1-A1. What is Plains GP?

Q1-A2. How Does Plains GP Make Money?

Q1-A3. Plains GP’s Revenue Segments & Core Income Sources

Q1-A4. Who Are Plains GP’s Competitors?

Q1-A5. Plains GP Key Events: Past 12 Months

Q1-A6. Step 1 Key Takeaways

🏰 Step 2: Plains GP’s Economic Moat, Growth & Capital Allocation

Q2-A1. Does Plains GP Have a Durable Economic Moat?

Q2-A2. Is Plains GP’s Growth Sustainable?

Q2-A3. How Does Plains GP Allocate Capital & Return Cash?

Q2-A4. Step 2 Key Takeaways

💰 Step 3: Is Plains GP Profitable? Financial Health Analysis

Q3-A2. How Profitable Is Plains GP? (Margins & ROIC)

Q3-A3. What Drives Plains GP’s Returns? (ROIC Breakdown)

Q3-A4. Are Plains GP’s Earnings High Quality?

Q3-A5. Is Plains GP’s Balance Sheet Healthy? (Debt & Leverage)

Q3-A6. Step 3 Key Takeaways

🔎 Step 4: Plains GP Forensic Accounting & Dilution Review

Q4-A1. Does Plains GP Have Accounting Red Flags?

Q4-A2. Is Plains GP Overspending? (Capex & Capital Cycle)

Q4-A3. How Sound Is Plains GP’s Cash Flow?

Q4-A4. Is Plains GP Diluting Shareholders?

Q4-A5. Data Integrity Check

Q4-A6. Step 4 Key Takeaways

👔 Step 5: Plains GP Management & Shareholder Alignment

Q5-A1. Can You Trust Plains GP’s Management? (Guidance Track Record)

Q5-A2. What Are Plains GP Insiders Doing?

Q5-A3. Is Plains GP’s Management Aligned With Shareholders?

Q5-A4. Step 5 Key Takeaways

⛵ Step 6: Plains GP Market Flow & Sentiment

Q6-A1. Analyst Consensus vs Plains GP Guidance

Q6-A2. What Is Plains GP’s Short Interest?

Q6-A3. Step 6 Key Takeaways

🚀 Step 7: Plains GP Catalysts & Price Triggers

Q7-A1. What Could Move Plains GP Stock? (Top 3 Catalysts)

Q7-A2. Plains GP’s Earnings Revision Trend

Q7-A3. Step 7 Key Takeaways

⚖️ Step 8: Is Plains GP Fairly Valued? Valuation Analysis

Q8-A1. Plains GP’s Key Valuation Multiples (P/E, EV/EBITDA)

Q8-A2. Plains GP vs Peers: Valuation Comparison

Q8-A3. Is Plains GP Cheap or Expensive vs Its History?

Q8-A4. What Growth Is Priced Into Plains GP? (Reverse DCF)

Q8-A4-1. What Growth Hurdle Does the Market Demand From Plains GP? (Reverse DCF Alternative)

Q8-A5. Valuation Cross-Check

Q8-A6. Plains GP’s Hidden Asset & Stake Valuation

Q8-A7. Final Valuation Adjustment

Q8-A8. Valuation Adjustment Score Calculation

💀 Step 9: What Are the Risks of Plains GP? Fatal Risks & Pre-Mortem

Q9-A1. What Are the Biggest Risks to Plains GP?

Q9-A2. How Sensitive Is Plains GP to the Economy?

Q9-A3. Plains GP Pre-Mortem: What Could Go Wrong?

Q9-A4. Risk Adjustment Score

🎯 Step 10: Plains GP Final Verdict: Score & Rating

Q10-A1. Investment Score & Rating

Q10-A2. Should You Buy Plains GP? (Recommendation)

Q10-A3. Investment Thesis in One Line

Q10-A4. Plains GP’s Price Trend & Key Drivers

Q10-A5. Action Plan

🕵️‍♂️ Deep Dive Analysis

Q1: Is Plains GP Holdings’ Permian Basin Concentration Its Biggest Weakness?

Q2: Can Plains GP Holdings’ 9.6x Forward P/E Be Justified by Its Transition to a Pure-Play Crude Transporter?

Q3: Will the Residual Line 901 and Line 63 Liabilities Materially Threaten Plains GP Holdings’ Cash Flows?

Q4: How Severely Does the Canadian NGL Divestiture Tax Burden Impact Plains GP Holdings’ Near-Term Liquidity?

Q5: Can Plains GP Holdings Sustain Its 10% Distribution Growth Strategy Amid Flat Permian Production?

Q6: How Does the $2.9 Billion Cactus III Acquisition Alter Plains GP Holdings’ Competitive Moat?

Q7: Is Plains GP Holdings’ Dual MLP/C-Corp Governance Structure a Red Flag for Institutional Alignment?

Q8: Does the 8.2% Short Interest in Plains GP Holdings Signal Hidden Operational Risks?

Q9: Will Plains GP Holdings’ New $2.7 Billion Credit Facility Provide Enough Ammunition for Strategic M&A?

Q10: Can Plains GP Holdings Offset $100 Million in Efficiency Costs Through System Optimization?